What does “positive hepatitis B antigen” mean?

May 28, 2022 Source: Cainiu Health
Dr. Jiang Weimin
Introduction
A positive hepatitis B surface antigen (HBsAg) test indicates that the individual is a hepatitis B carrier. Hepatitis B carriers are advised to undergo liver-related health examinations every six months. If the “big three” (HBsAg, HBeAg, and anti-HBc) or the “small three” (HBsAg, anti-HBe, and anti-HBc) are positive—i.e., patterns 135 or 145, respectively—the person is considered a hepatitis B carrier. Regardless of whether the serological pattern reflects “big three” positivity (indicating high viral replication) or “small three” positivity (often associated with lower viral activity), biannual liver examinations and clinical follow-up are recommended to monitor for potential hepatitis flare-ups.

In daily life, hepatitis B is a very common infectious disease; once diagnosed, timely and appropriate medical examinations are essential.

What does a positive hepatitis B antigen test mean?

A positive hepatitis B surface antigen (HBsAg) indicates that the individual is a hepatitis B carrier. Hepatitis B carriers are advised to undergo liver-related health check-ups every six months. A “big three positive” pattern (i.e., positivity for HBsAg, HBeAg, and anti-HBc—often referred to as “1, 3, 5”) or a “small three positive” pattern (i.e., positivity for HBsAg, anti-HBe, and anti-HBc—often referred to as “1, 4, 5”) both indicate chronic hepatitis B carriage. Regardless of whether the result reflects the “big three positive” or “small three positive” pattern, carriers should undergo liver health assessments every six months to monitor for potential hepatitis flare-ups. If hepatitis flares occur, prompt hepatoprotective and antiviral therapy is required.

It is recommended to perform a comprehensive liver function test. If liver function tests are normal, you are considered a healthy hepatitis B carrier who does not require treatment but should continue regular liver health monitoring. However, if liver function tests are abnormal, this suggests active hepatitis, necessitating antiviral and hepatoprotective treatment. Currently, first-line antiviral medications for chronic hepatitis B include entecavir and tenofovir, which effectively suppress hepatitis B virus replication, delay progression of hepatic fibrosis and hepatitis, and reduce the risk of hepatocellular carcinoma.

In addition to actively cooperating with physicians during treatment, patients must also pay attention to lifestyle modifications: avoid alcohol and tobacco, ensure adequate rest, refrain from staying up late, and cultivate healthy daily habits. We hope this information proves helpful to you!